Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort

Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials

(2021) Sonia L. Villegas et al.   EUROPEAN JOURNAL OF CANCER

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update

(2020) Kimberly H. Allison et al.   JOURNAL OF CLINICAL ONCOLOGY

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019

(2019) H J Burstein et al.   ANNALS OF ONCOLOGY

Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy

(2018) Alessandra Landmann et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

(2018) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

(2015) A. S. Coates et al.   ANNALS OF ONCOLOGY

High incidence of germlineBRCAmutation in patients with ER low-positive/PR low-positive/HER-2neunegative tumors

(2015) Rachel A. Sanford et al.   CANCER

Low ER+ Breast Cancer

(2014) Nika C. Gloyeske et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Which threshold for ER positivity? a retrospective study based on 9639 patients

(2014) M. Yi et al.   ANNALS OF ONCOLOGY

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

(2014) Gunter von Minckwitz et al.   LANCET ONCOLOGY

Personalized adjuvant therapies: Lessons from the past

(2013) Aron Goldhirsch   BREAST

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype

(2012) Brenda Deyarmin et al.   ANNALS OF SURGICAL ONCOLOGY

Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry

(2012) Takayuki Iwamoto et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

(2012) Michael Untch et al.   LANCET ONCOLOGY

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY